|1.82 0.14 (8.33%)||12-06 16:00|
|Targets||6-month :||2.52||1-year :||2.95|
|Resists||First :||2.16||Second :||2.52|
|Supports||First :||1.51||Second :||1.12|
|MAs||MA(5) :||1.67||MA(20) :||1.64|
|MA(100) :||5.95||MA(250) :||8.63|
|MACD||MACD :||-0.2||Signal :||-0.3|
|%K %D||K(14,3) :||52.9||D(3) :||50|
|52-week||High :||14.18||Low :||1.12|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PROK ] has closed below upper band by 30.4%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.93 - 1.94||1.94 - 1.95|
|Low:||1.6 - 1.61||1.61 - 1.61|
|Close:||1.81 - 1.82||1.82 - 1.83|
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||67 (M)|
|Shares Float||49 (M)|
|Held by Insiders||22.3 (%)|
|Held by Institutions||65.3 (%)|
|Shares Short||10,500 (K)|
|Shares Short P.Month||8,770 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-17.74|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-20.1 %|
|Return on Equity (ttm)||-29.2 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-80 (M)|
|Levered Free Cash Flow||-68 (M)|
|Price to Book value||-0.11|
|Price to Sales||0|
|Price to Cash Flow||-1.52|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|